Navigation Links
Pharmacyclics' Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
Date:4/16/2008

s well as angiogenesis, or the growth of new blood vessels that supply the tumors with nutrients and oxygen. Activation of Factor VII (Factor VIIa) by tissue factor also leads to the high incidence of thrombotic complications seen in cancer patients. PCI-27483 selectively inhibits Factor VIIa when it is complexed with tissue factor.

"We're encouraged by the promising preclinical results with PCI-27483 as we broaden our portfolio of product opportunities," said Richard A. Miller, M.D., president and chief executive officer of Pharmacyclics. "We are working to move additional drug candidates forward from our diverse pipeline, including an HDAC inhibitor, now in a Phase 1 clinical trial for solid tumors, and motexafin gadolinium, which is currently in two Phase 2 trials sponsored by the National Cancer Institute."

About Pharmacyclics

Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways and mechanisms. More information about the company, its technology, and products can be found at http://www.pharmacyclics.com. Pharmacyclics(R) and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.

NOTE: Other than statements of historical fact, the statements made in this press release about plans for filing an IND for PCI-27483, and other future plans for our clinical trials, progress of and reports of results from preclinical and clinical studies, clinical development plans and product development and corporate partnering activities are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. The words "project," "believe," "will," "may," "continue," "plan," "expect," "intend," "anticipate," variations of such w
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
4. Genmab A/S - Company Announcement: Novel Insights into HuMax-EGFr Mechanisms of Action Published in PNAS
5. FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment
6. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
7. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
8. Parion Sciences Announces Phase I Clinical Results for Novel Dry Mouth Treatment
9. NeoVista Presents One Year Data on Novel Wet AMD Therapy at Macula Society
10. Sangart Completes Enrollment in Phase III Study of Its Novel Blood Substitute Hemospan
11. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... HELSINKI, Dec. 14 Cancer patients in ... with the introduction of RapidArc® radiotherapy technology from ... at the only private radiotherapy clinic in the ... are using this fast and precise form of ... and cancers of the abdomen and prostate. ,, ...
(Date:12/14/2009)... Dec. 14 Accuray Incorporated (Nasdaq: ... of radiosurgery, announced today that the first CyberKnife® ... at the University Hospital of Liege. ,, ... is one of the largest hospitals in Euregio, ... ,, "With a full range of cancer treatments, ...
(Date:12/14/2009)... Travelers of Interstate 70 west of Indianapolis ... bit more colorful when 10 multicolored art forms are ... going home , will eventually include 34 total ... student at Herron School of Art and Design, through ... ,, Eli Lilly and Company (NYSE: ...
Breaking Medicine Technology:Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 2Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 3First CyberKnife in Belgium to be Installed at Leading University Hospital 2First CyberKnife in Belgium to be Installed at Leading University Hospital 3Public Art to Complete Transformation of Key Gateway into Indianapolis 2Public Art to Complete Transformation of Key Gateway into Indianapolis 3Public Art to Complete Transformation of Key Gateway into Indianapolis 4Bioidentical Hormones a True Prevention for Breast Cancer 59889 1Bioidentical Hormones a True Prevention for Breast Cancer 59889 2Gamida Cell and Cellerix Partner on Feasibility Study 14558 1Gamida Cell and Cellerix Partner on Feasibility Study 14558 2Gamida Cell and Cellerix Partner on Feasibility Study 14558 3Uroplasty to Issue Second Fiscal Quarter Results on November 2 2009 5634 1Uroplasty to Issue Second Fiscal Quarter Results on November 2 2009 5634 2
... Decline in Global Measles Deaths, Joint News Release: ... and WASHINGTON, Nov. 29, Measles deaths in Africa fell ... 396,000 to 36,000, reaching the,United Nations 2010 goal to ... spectacular gains achieved in Africa helped generate a strong,decline ...
... Action Council,joins organizations and individuals across the country and ... Day, December 1, 2007. Since 1988,World AIDS Day has ... and to reinvigorate global, national, regional,and local efforts to ... World AIDS Day is leadership. Nearly 27,years since it ...
Other Medicine Technology:Measles Deaths in Africa Plunge by 91% 2Measles Deaths in Africa Plunge by 91% 3Measles Deaths in Africa Plunge by 91% 4AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic 2
(Date:12/15/2009)... caring, conscientious practice you have ever been a part of. We ... we can help to achieve this goal and meet your expectations." ... ... The Dermatology Center of Dallas, a Dallas based, full-service medical and ... Foshee, MD in their practice. Dr. Foshee joins James H. ...
(Date:12/15/2009)... 1, 2010 Oregon will require that certain businesses with large ... external defibrillator (AED) readily available. Fire and rescue personnel agree ... is a good investment. , ... ... 2010 Oregon will require that certain businesses with large areas ...
(Date:12/15/2009)... San Diego Hospice and The Institute for Palliative Medicine ... 14, 2009. Mr. Price has been known for his ... business, community and personal life. Mr. Price was a ... of philanthropy and the role it plays in the ... countless philanthropic efforts. We extend our condolences to the ...
(Date:12/15/2009)... UT Southwestern Medical Center researchers have provided the ... observable characteristics seen in patients with an extremely ... online and in the December issue of the ... suggest that patients with atypical progeroid syndrome (APS) ... with two similar but more well-defined accelerated aging ...
(Date:12/14/2009)... more… , ... Santa Barbara, California ... scientists at University of Michigan, have developed synthetic particles that ... blood cells, including softness, flexibility, and the ability to carry ... natural red blood cells is to carry oxygen, and the ...
Breaking Medicine News(10 mins):Health News:Jeri Beth “J.B.” Foshee, MD Joins Dermatology Center of Dallas 2Health News:QuickMedical Responds to Oregon Bill Requiring Businesses to Carry Defibrillators 2Health News:QuickMedical Responds to Oregon Bill Requiring Businesses to Carry Defibrillators 3Health News:San Diego Hospice and The Institute for Palliative Medicine on the Passing of Sol Price 2Health News:Researchers ID traits of people with rare accelerated aging syndrome 2Health News:Synthetic Red Blood Cells Developed 2Health News:Synthetic Red Blood Cells Developed 3
... tea can soothe the skin damages caused by Cancer Radiation ... ,Studies were conducted on patients using Green Tea and Black ... laboratory. This action is happening due to the high amounts ... Tea has lower anti-inflammatory properties than Green Tea. In Human ...
... should appoint a brand ambassador to boost its health tourism ... based abroad. // ,The Federation of Kerala Associations in ... Canada, has asked the Indian and Kerala governments to promote ... ,"The brand ambassador should attract the attention of the entire ...
... Welfare, has a contingency plan to manage human ... surveillance, preventive public health// measures, clinical management, stockpiling ... activities. ,This plan was operationalized during ... Nundurbar and Jalgaon districts of Maharashtra, Surat District ...
... bird flu in Quebec is not true, and is just ... the man at the helm of infection control at the ... no patient, no nothing." ,The rumors were sparked ... had enabled a report of a nine-year-old boy ill and ...
... RU-486 was used by scientists in mice that were bred ... warding off potential tumors.// , ,This is thought ... to inhibit the hormone, progesterone. This is indeed a teaser ... blocker as an option for women carrying the breast cancer ...
... report in the Medical Journal has cast aspersions on the findings ... pediatrician Professor Sir Roy Meadow// , ,A paper published in ... of the second infant deaths occurring in families who had lost ... natural causes. This was substantiated by the research led by Prof ...
Other Medicine News:Health News:RU-486, The Abortion Pill, May Quell The Breast Cancer Gene 2
... B6 makes it possible to determine the,vitamin ... method. The kits includes all reagents in,ready ... of the samples with,exception of the columns. ... simultaneous handling of many analytes in a ...
ELISA kit for the quantitative determination of autoantibodies to tissue transglutaminase (tTG) in serum....
... Increased volume for use with 4, 8, or ... permits withdrawal of nearly all of the solution. ... solution. Made of natural virgin polystyrene containing no ... Sterilized by irradiation. Dimensions: 78 mm W x ...
Volume: 25 ml; Volume Graduation: 2/10 ml...
Medicine Products: